170 related articles for article (PubMed ID: 22936063)
1. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Voutsina A; Tzardi M; Kalikaki A; Zafeiriou Z; Papadimitraki E; Papadakis M; Mavroudis D; Georgoulias V
Mod Pathol; 2013 Feb; 26(2):302-13. PubMed ID: 22936063
[TBL] [Abstract][Full Text] [Related]
2. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
[TBL] [Abstract][Full Text] [Related]
7. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
8. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
10. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
11. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
13. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
14. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
Mao C; Zhou J; Yang Z; Huang Y; Wu X; Shen H; Tang J; Chen Q
PLoS One; 2012; 7(5):e36653. PubMed ID: 22586484
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M; Personeni N; Bozzarelli S; Baretti M; Basso G; Bianchi P; Tronconi MC; Pressiani T; Grizzi F; Giordano L; Malesci A; Alloisio M; Laghi L; Santoro A; Rimassa L
Cancer Med; 2016 Feb; 5(2):256-64. PubMed ID: 26715198
[TBL] [Abstract][Full Text] [Related]
16. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
18. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
